NYSEArca - Delayed Quote USD

iShares China Large-Cap ETF (FXI)

25.27 +0.47 (+1.90%)
At close: April 24 at 4:00 PM EDT
25.04 -0.23 (-0.91%)
After hours: April 24 at 7:59 PM EDT
Loading Chart for FXI
DELL
  • Previous Close 24.80
  • Open 25.22
  • Bid --
  • Ask --
  • Day's Range 25.11 - 25.29
  • 52 Week Range 20.86 - 30.54
  • Volume 44,703,789
  • Avg. Volume 42,926,538
  • Net Assets 4.48B
  • NAV 24.86
  • PE Ratio (TTM) 8.18
  • Yield 3.17%
  • YTD Daily Total Return 3.20%
  • Beta (5Y Monthly) 1.06
  • Expense Ratio (net) 0.74%

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.

iShares

Fund Family

China Region

Fund Category

4.48B

Net Assets

2004-10-05

Inception Date

Performance Overview: FXI

Trailing returns as of 4/23/2024. Category is China Region.

YTD Return

FXI
3.20%
Category
3.05%
 

1-Year Return

FXI
9.86%
Category
18.48%
 

3-Year Return

FXI
17.58%
Category
17.29%
 

People Also Watch

Holdings: FXI

Top 10 Holdings (58.08% of Total Assets)

SymbolCompany% Assets
0700.HK
Tencent Holdings Limited 9.85%
9988.HK
Alibaba Group Holding Limited 8.63%
3690.HK
Meituan 8.21%
00939
00939 6.99%
01398
01398 4.93%
9999.HK
NetEase, Inc. 4.27%
03988
03988 4.05%
9618.HK
JD.com, Inc. 4.02%
9888.HK
Baidu, Inc. 3.65%
1810.HK
Xiaomi Corporation 3.47%

Sector Weightings

SectorFXI
Energy   6.40%
Technology   3.48%
Real Estate   1.77%
Industrials   1.67%
Healthcare   1.14%
Utilities   0.41%

Related ETF News

Research Reports: FXI

  • Analyst Report: Biogen Inc.

    Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

    Rating
    Price Target
     
  • Analyst Report: Netflix, Inc.

    Netflix’s relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with almost 250 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm recently began introducing ad-supported subscription plans, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.

    Rating
    Price Target
     
  • Analyst Report: Occidental Petroleum Corporation

    Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2023, the company reported net proved reserves of nearly 4.0 billion barrels of oil equivalent. Net production averaged 1,234 thousand barrels of oil equivalent per day in 2023 at a ratio of roughly 50% oil and natural gas liquids and 50% natural gas.

    Rating
    Price Target
     
  • Analyst Report: Meta Platforms, Inc.

    Meta is the world’s largest online social network, with nearly 4 billion family of apps monthly active users. Users engage with each other in different ways, exchanging messages and sharing news events, photos, and videos. The firm’s ecosystem consists mainly of the Facebook app, Instagram, Messenger, WhatsApp, and many features surrounding these products. Users can access Facebook on mobile devices and desktops. Advertising revenue represents more than 90% of the firm’s total revenue, with more than 45% coming from the U.S. and Canada and over 20% from Europe.

    Rating
    Price Target
     

Related Tickers